## **Patent Claims**

1) A composition comprising one or more salts of tiotropium  $\underline{1}$  and one or more pharmacologically acceptable salts of a compound of formula  $\underline{2'}$ 

5

10

HO HN 
$$R^2$$
  $R^4$   $2'$ 

wherein

R<sup>1</sup> and R<sup>2</sup>

which may be identical or different denote hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl;

R<sup>3</sup> and R<sup>4</sup> which may be identical or different denote hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, -O-C<sub>1</sub>-

C<sub>4</sub>-alkyl, - C<sub>1</sub>-C<sub>4</sub>-alkylene-O-C<sub>1</sub>-C<sub>4</sub>-alkyl or

R<sup>3</sup> and R<sup>4</sup> together denote one of the bridging groups

- C<sub>1</sub>-C<sub>4</sub>-alkylene- or -O-C<sub>1</sub>-C<sub>4</sub>-alkylene-O-; together with a

pharmaceutically acceptable carrier.

- 15 2) The composition according to claim 1 wherein the one or more salts of tiotropium 1 is in the form of the chloride, bromide, iodide, methanesulphonate, paratoluene sulphonate or methyl sulphate.
- 3) The composition according to claim 1 wherein, for the compound of formula 2', R¹ and R² which may be identical or different denote hydrogen, methyl or ethyl;

  20 R³ and R⁴ which may be identical or different denote hydrogen, methyl, ethyl, propyl, butyl, methoxy, ethoxy, methyoxymethyl, or methoxyethyl, or R³ and R⁴ together denote one of the bridging groups propylene, butylene, -O-ethylene-O- or -O-propylene-O-.

- 4) The composition according to claim 1 wherein the one or more salts of tiotropium  $\underline{1}$  and the one or more pharmacologically acceptable salts of compound  $\underline{2'}$  are either present together in a single preparation or are contained in two separate preparations.
- 5 5) The composition according to claim 4 wherein the weight ratios of  $\underline{1}$  to  $\underline{2}$  are in the range from 1:300 to 30:1.
  - The composition according to claim 4 wherein a single application corresponds to a dosage of the combination of active substances  $\underline{1}$  and  $\underline{2}$  of 0.01 to 10000 $\mu$ g.
  - 7) The composition according to claim 4 that it is in the form of a formulation suitable for inhalation.
- 8) The composition according to claim 7 wherein the form is selected from the group consisting of inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.
  - 9) The composition according to claim 8 comprising an inhalable powder which contains  $\underline{1}$  and  $\underline{2}$  in admixture with suitable physiologically acceptable excipients selected from the group consisting of monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures of these excipients.
  - 10) The composition according to claim 9 wherein the excipient has a maximum average particle size of 250μm.
  - 11) The composition according to claim 9 contained in a capsule.
  - 12) The composition according to claim 8 in the form of an inhalable powder consisting essentially of active substances  $\underline{1}$  and  $\underline{2}$ .

30

25

10

20

5

10

- 13) The composition according to claim 8 in the form of a propellant-containing inhalable aerosol comprising active substances <u>1</u> and <u>2</u> in dissolved or dispersed form.
- 14) The composition according to claim 8 in the form of a propellant-free inhalable solution or suspension comprising water, ethanol or a mixture of water and ethanol as a solvent.
- 15) A method for treating inflammatory or obstructive diseases of the respiratory tract comprising the administration to a patient of a therapeutically effective amount of the composition according to claim  $\underline{1}$ .